ORY Oryzon Genomics

Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)

Edison Investment Research Limited
Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)

20-Jan-2020 / 10:01 GMT/BST

 

London, UK, 20 January 2020

Edison issues outlook on Oryzon Genomics (ORY)

As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa clinical trials with both assets at eight conferences last year. All readouts were still interim. This and the fact that Phase IIa trials, in general, are relatively small and focus on safety meant that the share price did not reach new highs despite all readouts being positive. Final results from the trials are expected throughout 2020-21 and Oryzon is already initiating a Phase IIb trial with its CNS asset in borderline personality disorder (BPD). This will provide plenty more catalysts in the coming months. Our valuation is slightly higher at €454m or €9.9/share.

 

Our valuation of Oryzon is slightly higher at €454m or €9.9 per share, up from €437m or €9.5 per share, mainly due to rolling our model forward. We leave our assumptions unchanged. The main near-term catalysts include vafidemstat Phase IIa REIMAGINE-AD data from AD patients in Q220; vafidemstat Phase IIa ETHERAL EU six-month interim trial results in H120; updated data from iadademstat Phase IIa CLEPSIDRA in SCLC and Phase IIa ALICE in AML some time in 2020.


to view the full report.

 

to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the .

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Jonas Peciulis, +44 (0)20 3077 5728

 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

956701  20-Jan-2020 

fncls.ssp?fn=show_t_gif&application_id=956701&application_name=news&site_id=research_pool
EN
20/01/2020

Underlying

ORYOryzon Genomics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oryzon Genomics

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
12/17/25 December 17, 2025 1 FR
 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON Announces the Voting Results of December 2025 Extraordinary Gen...

ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting 37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share ...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON Presents Data for Iadademstat Combinations in AML at the Americ...

ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting 100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good tolerability70% of patients derived to Hematopoietic Stem Cell Transplantation (HSCT) 67% CCR at the expansion dose in study evaluating iadademstat plus gilterinib in FLT3-mutated relapsed/refractory AML patients; 47% CR+CRhTreatment was safe and well tolerate...

December 9, 2025 1 EN
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
11/12/25 November 12, 2025 1 FR
 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON Reports Financial Results and Corporate Update for Quarter Ende...

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS(Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmitReinforcing company’s clinical, strategy and regulatory teamsExpansion of ongoing Phase IIb in schizophrenia into other EU countries continuesPreparations continue for new Phase II trial in aggression in Autism Spec...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch